LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
OLAnzaPiNE-3: Low-Dose vs Standard-Dose Olanzapine in Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy in Solid Tumor
By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned…
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023]
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr.…
AsCas12a Gene Editing of HBG1/2Promoters with EDIT-301 Results [ASH 2023]
Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic…
By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo…
Managing High-Risk Hematologic Malignancies in the Community [ASH 2023]
Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How…
In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL),…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical…
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi,…
By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…